Asset Acquisition and License Agreements - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended
	Aug. 31, 2025	Apr. 30, 2025	Feb. 29, 2024	Nov. 30, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Business Combination [Line Items]
Acquired in-process research and development					$ 947,862	$ 10,000	$ 19,000
Upfront and milestone payment values					8,210,138	7,713,412
Saniona \| Upfront Payment
Business Combination [Line Items]
Acquired in-process research and development	$ 42,500
Saniona \| Potential Milestone Payment
Business Combination [Line Items]
Upfront and milestone payment values					$ 992,500
Redx Pharma \| Upfront Payment
Business Combination [Line Items]
Acquired in-process research and development			$ 10,000
Redx Pharma \| Potential Milestone Payment
Business Combination [Line Items]
Upfront and milestone payment values						$ 870,000
Autifony Therapeutics \| Upfront Payment
Business Combination [Line Items]
Acquired in-process research and development				$ 18,000
Autifony Therapeutics \| Potential Milestone Payment
Business Combination [Line Items]
Upfront and milestone payment values							$ 752,500
Chimerix
Business Combination [Line Items]
Share price (in dollars per share)		$ 8.55
Total cash consideration paid to Chimerix		$ 944,154